Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis After Myeloablative Unrelated Donor Peripheral Blood Stem Cell Transplantation
NCT ID: NCT03602898
Last Updated: 2021-06-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2021-06-01
2023-09-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
NCT03128359
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
NCT02208037
Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation
NCT03246906
Comparing Cyclophosphamide and Abatacept With Standard of Care Treatment Following Stem Cell Transplantation
NCT03680092
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CONDITIONING REGIMENS: Participants receive 1 of 3 regimens and are randomized to 1 of 3 arms for GVHD prophylaxis.
REGIMEN A: Participants undergo total body irradiation (TBI) twice daily (BID) on days -6 to -4 (-7 to -4 for those \< 18 years), then receive cyclophosphamide IV over 1-2 hours on days -3 and -2. Participants randomized to Arm 2 only receive TBI on days -3 to -1 (-4 to -1 for those \< 18 years).
REGIMEN B: Participants receive fludarabine phosphate IV and busulfan IV every 6 hours on days -5 to -2.
REGIMEN C: Participants receive busulfan orally (PO) or IV every 6 hours on days -7 to -4 and cyclophosphamide IV over 1-2 hours on days -3 and -2.
Myelofibrosis or other myeloproliferative neoplasms: Participants \>= 18 years receive cyclophosphamide IV over 1-2 hours on days -7 and -6 and busulfan IV on days -5 to -2. Participants \< 17 years receive busulfan IV every 6 hours on days -7 to -4 and cyclophosphamide IV on days -3 and -2.
All participants undergo peripheral blood stem cell transplantation on day 0.
ARM 1: Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV twice daily (BID) tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
ARM 2: Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
ARM 3: Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up at 6 months, then annually up to 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 (ATG, tacrolimus or cyclosporine, methotrexate)
Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive anti-thymocyte globulin IV over 4-6 hours on days -3 to -1. Beginning day -1, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11 in the absence of disease progression or unacceptable toxicity.
Anti-Thymocyte Globulin
Given IV
Busulfan
Given IV or PO
Cyclophosphamide
Given IV
Cyclosporine
Given IV or PO
Fludarabine Phosphate
Given IV
Methotrexate
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo peripheral blood stem cell transplantation
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Arm 2 (cyclophosphamide, tacrolimus or cyclosporine)
Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Participants receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 5, participants also receive tacrolimus IV or cyclosporine IV BID tapered at day 50 in the absence of disease progression or unacceptable toxicity.
Busulfan
Given IV or PO
Cyclophosphamide
Given IV
Cyclosporine
Given IV or PO
Fludarabine Phosphate
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo peripheral blood stem cell transplantation
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Arm 3 (tacrolimus or cyclosporine, methotrexate)
Participants receive conditioning regimen (see detailed description) and then undergo peripheral blood stem cell transplantation on day 0. Beginning day -1, participants receive tacrolimus IV or cyclosporine IV BID tapered at day 50, and methotrexate IV on days 1, 3, 6 and 11.
Busulfan
Given IV or PO
Cyclophosphamide
Given IV
Cyclosporine
Given IV or PO
Fludarabine Phosphate
Given IV
Methotrexate
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo peripheral blood stem cell transplantation
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anti-Thymocyte Globulin
Given IV
Busulfan
Given IV or PO
Cyclophosphamide
Given IV
Cyclosporine
Given IV or PO
Fludarabine Phosphate
Given IV
Methotrexate
Given IV
Peripheral Blood Stem Cell Transplantation
Undergo peripheral blood stem cell transplantation
Quality-of-Life Assessment
Ancillary studies
Questionnaire Administration
Ancillary studies
Tacrolimus
Given IV or PO
Total-Body Irradiation
Undergo TBI
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Acute lymphocytic leukemia (ALL) in complete remission (CR)1 with high risk features defined as evidence of adverse cytogenetics such as t(9;22), t(1;19), t(4;11), or MLL rearrangements or presence of minimal residual disease
* Acute myeloid leukemia (AML) in CR1 with high risk features defined as:
* Intermediate or adverse risk disease as defined by European LeukemiaNet (ELN) 2017
* Greater than 1 cycle of induction therapy required to achieve remission
* Preceding myelodysplastic syndrome (MDS) or myelofibrosis
* Therapy-related AML
* Presence of FLT3 internal tandem duplications
* French-American-British (FAB) M6 or M7 classification
* Acute leukemia (ALL or AML) in second (2nd) or greater CR (CR ≥ 2)
* Refractory or relapsed AML with =\< 5% bone marrow blasts and no circulating blasts by morphology or proven extramedullary disease
* Myelodysplastic syndrome (MDS) with following high risk features: poor cytogenetics (-7, inv(3)/t(3q)/del(3q), del(7q) or complex cytogenetics defined as \>= 3 abnormalities), Revised International Prognostic Scoring System (IPSS-R) risk group intermediate or higher, or treatment-related MDS
* Any phase of MDS if patient is \< 21 years of age
* Chronic myelogenous leukemia (CML) beyond 1st chronic phase or resistant to tyrosine kinase inhibitors (adults)
* Chronic myelomonocytic leukemia (CMML)
* Myeloproliferative disorders/myelofibrosis
* Hodgkin or non-Hodgkin lymphoma: relapsed chemotherapy-sensitive (complete or partial response)
* Female patients must have negative standard pregnancy test (all women of child bearing-potential must have test performed)
* Ability to understand and the willingness to sign a written informed consent document
* For patients with acute leukemia, CR is defined as =\< 5% marrow blasts by morphology. CR with incomplete count recovery is allowed
* DONOR INCLUSION
* Unrelated donors matched for human leukocyte antigen (HLA)-A, B, C, DRB1 and DQB1 by high resolution typing
* Donors are excluded when preexisting immunoreactivity is identified that would jeopardize donor hematopoietic cell engraftment. This determination is based on the standard practice of the individual institution. The recommended procedure for patients with 10 of 10 HLA allele level (phenotypic) match is to obtain a panel reactive antibody (PRA) screens to class I and class II antigens for all patients before hematopoietic cell transplantation (HCT). If the PRA shows \> 10% activity, then flow cytometric or B and T cell cytotoxic cross matches should be obtained. The donor should be excluded if any of the cytotoxic cross match assays are positive
* Only granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood stem cell (PBSC) will be permitted as a hematopoietic stem cell (HSC) source on this protocol
* Donors must meet the selection criteria for administration of G-CSF and apheresis defined based on each institution's standard practice protocol for unrelated donors
* Donors must be capable of giving informed consent
Exclusion Criteria
* Performance status: Karnofsky score \<60 or Lansky score \<50 for patients \<16 years old
* Uncontrolled infection. The protocol principal investigator (PI) will be final arbiter if there is uncertainty regarding whether a previous infection is under adequate control to allow enrollment in the study
* Positive serology for human immunodeficiency virus (HIV)-1, 2 or human T-lymphotropic virus (HTLV)-1, 2
* Left ventricular ejection fraction \< 45%. Uncontrolled arrhythmias or symptomatic cardiac disease
* Symptomatic pulmonary disease. Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), diffusion capacity of the lung for carbon monoxide (DLCO) =\< 50% of predicted (corrected for hemoglobin). Use of continuous supplemental oxygen
* Calculated (Cockroft-Gault; or appropriate calculation for pediatric patients) serum creatinine clearance \<60 mL/min. If the calculated CrCl is 50-60 mL/min, but a measured CrCl by 24 hour urine collection is \> 60 mL/min, this measurement is acceptable
* Total serum bilirubin more than twice upper normal limit
* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) more than 3-fold higher than laboratory upper normal limits
* History of allergy or anaphylactic reaction to rabbit protein or to any product excipients
* Subjects may not be enrolled in other investigational trials with acute or chronic GVHD as the primary endpoint
* DONOR EXCLUSION
* Donor who will exclusively donate marrow
* Donors who are HIV-positive
* Potential donors who for psychological, physiological, or medical reasons cannot tolerate administration of G-CSF or apheresis
* Donors who are allergic to filgrastim or Escherichia (E.) coli-derived proteins
* Donor-related risks to recipients
* Positive anti-donor lymphocytotoxic crossmatch
* Pregnant or lactating women
* Prior malignancy within the last 5 years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Fred Hutchinson Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Masumi Ueda Oshima
Role: PRINCIPAL_INVESTIGATOR
Fred Hutch/University of Washington Cancer Consortium
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2018-01302
Identifier Type: REGISTRY
Identifier Source: secondary_id
9954
Identifier Type: OTHER
Identifier Source: secondary_id
RG1001747
Identifier Type: OTHER
Identifier Source: secondary_id
9954
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.